Scholar Rock Holding Corp (SRRK) stock
SRRKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$45.08+0.54 (+1.21%)
Close on Nov 17, 2026Market cap $5.49BP/E –Yield –
Scholar Rock r&d expenses
Research and development expenses are spending on new products and technology.
Scholar Rock's R&D Expenses for the twelve months ending Jun 30, 2026 was $207.41M, down 1.3% year over year. For fiscal 2025 it was $208.44M, up 12.9% from the year before. The highest annual figure on record is $208.44M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $208.44M | +12.9% |
| FY2024 | Dec 31, 2024 | $184.55M | +51.4% |
| FY2023 | Dec 31, 2023 | $121.90M | -2.0% |
| FY2022 | Dec 31, 2022 | $124.44M | +14.7% |
| FY2021 | Dec 31, 2021 | $108.47M | +46.5% |
| FY2020 | Dec 31, 2020 | $74.06M | +36.6% |
| FY2019 | Dec 31, 2019 | $54.22M | +49.3% |
| FY2018 | Dec 31, 2018 | $36.31M | +82.1% |
| FY2017 | Dec 31, 2017 | $19.94M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $58.23M | -6.7% |
| Q1 FY2026 | Mar 31, 2026 | $51.81M | +6.4% |
| Q4 FY2025 | Dec 31, 2025 | $46.88M | -6.9% |
| Q3 FY2025 | Sep 30, 2025 | $50.49M | +3.6% |
| Q2 FY2025 | Jun 30, 2025 | $62.40M | +47.3% |
| Q1 FY2025 | Mar 31, 2025 | $48.68M | +13.0% |
| Q4 FY2024 | Dec 31, 2024 | $50.37M | +44.1% |
| Q3 FY2024 | Sep 30, 2024 | $48.72M | +60.6% |
| Q2 FY2024 | Jun 30, 2024 | $42.37M | +57.7% |
| Q1 FY2024 | Mar 31, 2024 | $43.09M | +44.9% |
| Q4 FY2023 | Dec 31, 2023 | $34.96M | +18.1% |
| Q3 FY2023 | Sep 30, 2023 | $30.34M | -9.1% |
| Q2 FY2023 | Jun 30, 2023 | $26.87M | -16.2% |
| Q1 FY2023 | Mar 31, 2023 | $29.74M | +1.3% |
| Q4 FY2022 | Dec 31, 2022 | $29.61M | +1.9% |
| Q3 FY2022 | Sep 30, 2022 | $33.39M | +6.8% |
| Q2 FY2022 | Jun 30, 2022 | $32.07M | +25.3% |
| Q1 FY2022 | Mar 31, 2022 | $29.37M | +30.2% |
| Q4 FY2021 | Dec 31, 2021 | $29.05M | +33.4% |
| Q3 FY2021 | Sep 30, 2021 | $31.27M | +70.1% |
| Q2 FY2021 | Jun 30, 2021 | $25.60M | +50.6% |
| Q1 FY2021 | Mar 31, 2021 | $22.55M | +33.4% |
| Q4 FY2020 | Dec 31, 2020 | $21.78M | +54.9% |
| Q3 FY2020 | Sep 30, 2020 | $18.38M | +17.1% |
| Q2 FY2020 | Jun 30, 2020 | $17.00M | +23.9% |
| Q1 FY2020 | Mar 31, 2020 | $16.90M | +57.4% |
| Q4 FY2019 | Dec 31, 2019 | $14.06M | +38.9% |
| Q3 FY2019 | Sep 30, 2019 | $15.70M | +94.8% |
| Q2 FY2019 | Jun 30, 2019 | $13.72M | +20.1% |
| Q1 FY2019 | Mar 31, 2019 | $10.74M | +60.3% |
| Q4 FY2018 | Dec 31, 2018 | $10.13M | +47.0% |
| Q3 FY2018 | Sep 30, 2018 | $8.06M | +68.7% |
| Q2 FY2018 | Jun 30, 2018 | $11.42M | +142.5% |
| Q1 FY2018 | Mar 31, 2018 | $6.70M | – |
| Q4 FY2017 | Dec 31, 2017 | $6.89M | – |
| Q3 FY2017 | Sep 30, 2017 | $4.78M | – |
| Q2 FY2017 | Jun 30, 2017 | $4.71M | – |
See a number that looks wrong?